These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32797307)

  • 1. Reliability of dopamine transporter PET measurements with [
    Kerstens VS; Fazio P; Sundgren M; Matheson GJ; Franzén E; Halldin C; Cervenka S; Svenningsson P; Varrone A
    EJNMMI Res; 2020 Aug; 10(1):95. PubMed ID: 32797307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal DAT changes measured with [
    Kerstens VS; Fazio P; Sundgren M; Brumberg J; Halldin C; Svenningsson P; Varrone A
    Neuroimage Clin; 2023; 37():103347. PubMed ID: 36822016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis of ¹⁸F-(E)-N-(3-Iodoprop-2-Enyl)-2β-Carbofluoroethoxy-3β-(4'-Methyl-Phenyl) Nortropane Binding to the Dopamine Transporter in Parkinson Disease.
    Fazio P; Svenningsson P; Forsberg A; Jönsson EG; Amini N; Nakao R; Nag S; Halldin C; Farde L; Varrone A
    J Nucl Med; 2015 May; 56(5):714-20. PubMed ID: 25791993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [
    Honhar P; Ebrahimian Sadabad F; Tinaz S; Gallezot JD; Dias M; Naganawa M; Yang Y; Henry S; Hillmer AT; Gao H; Najafzadeh S; Comley R; Nabulsi N; Huang Y; Finnema SJ; Carson RE; Matuskey D
    Brain Commun; 2024; 6(5):fcae345. PubMed ID: 39429243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients.
    Sonni I; Fazio P; Schain M; Halldin C; Svenningsson P; Farde L; Varrone A
    J Nucl Med; 2016 Oct; 57(10):1529-1534. PubMed ID: 27230923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Kerstens VS; Fazio P; Sundgren M; Halldin C; Svenningsson P; Varrone A
    EJNMMI Res; 2023 Apr; 13(1):29. PubMed ID: 37017878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification and discriminative power of
    Delva A; Van Weehaeghe D; van Aalst J; Ceccarini J; Koole M; Baete K; Nuyts J; Vandenberghe W; Van Laere K
    Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1913-1926. PubMed ID: 31776633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine transporter imaging with [
    Jakobson Mo S; Axelsson J; Jonasson L; Larsson A; Ögren MJ; Ögren M; Varrone A; Eriksson L; Bäckström D; Af Bjerkén S; Linder J; Riklund K
    EJNMMI Res; 2018 Nov; 8(1):100. PubMed ID: 30443684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified quantification of [
    Brumberg J; Kerstens V; Cselényi Z; Svenningsson P; Sundgren M; Fazio P; Varrone A
    J Cereb Blood Flow Metab; 2021 Jun; 41(6):1291-1300. PubMed ID: 32955955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related decline in dopamine transporter in human brain using PET with a new radioligand [¹⁸F]FE-PE2I.
    Shingai Y; Tateno A; Arakawa R; Sakayori T; Kim W; Suzuki H; Okubo Y
    Ann Nucl Med; 2014 Apr; 28(3):220-6. PubMed ID: 24385293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of dopamine transporter in human brain using PET with 18F-FE-PE2I.
    Sasaki T; Ito H; Kimura Y; Arakawa R; Takano H; Seki C; Kodaka F; Fujie S; Takahata K; Nogami T; Suzuki M; Fujiwara H; Takahashi H; Nakao R; Fukumura T; Varrone A; Halldin C; Nishikawa T; Suhara T
    J Nucl Med; 2012 Jul; 53(7):1065-73. PubMed ID: 22689927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
    Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
    Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET imaging of dopamine transporters with [(18)F]FE-PE2I: Effects of anti-Parkinsonian drugs.
    Bang JI; Jung IS; Song YS; Park HS; Moon BS; Lee BC; Kim SE
    Nucl Med Biol; 2016 Feb; 43(2):158-64. PubMed ID: 26872440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproducibility of PET measurement for presynaptic dopaminergic functions using L-[β-(11)C]DOPA and [(18)F]FE-PE2I in humans.
    Suzuki M; Ito H; Kodaka F; Takano H; Kimura Y; Fujiwara H; Sasaki T; Takahata K; Nogami T; Nagashima T; Nengaki N; Kawamura K; Zhang MR; Varrone A; Halldin C; Okubo Y; Suhara T
    Nucl Med Commun; 2014 Mar; 35(3):231-7. PubMed ID: 24468851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [
    Marner L; Korsholm K; Anderberg L; Lonsdale MN; Jensen MR; Brødsgaard E; Denholt CL; Gillings N; Law I; Friberg L
    EJNMMI Res; 2022 Sep; 12(1):56. PubMed ID: 36070114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility.
    Hirvonen J; Johansson J; Teräs M; Oikonen V; Lumme V; Virsu P; Roivainen A; Någren K; Halldin C; Farde L; Hietala J
    J Cereb Blood Flow Metab; 2008 May; 28(5):1059-69. PubMed ID: 18183028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro autoradiography and in vivo evaluation in cynomolgus monkey of [18F]FE-PE2I, a new dopamine transporter PET radioligand.
    Varrone A; Steiger C; Schou M; Takano A; Finnema SJ; Guilloteau D; Gulyás B; Halldin C
    Synapse; 2009 Oct; 63(10):871-80. PubMed ID: 19562698
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Li W; Lao-Kaim NP; Roussakis AA; Martín-Bastida A; Valle-Guzman N; Paul G; Loane C; Widner H; Politis M; Foltynie T; Barker RA; Piccini P
    Mov Disord; 2018 Jan; 33(1):117-127. PubMed ID: 29082547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease.
    Prunier C; Payoux P; Guilloteau D; Chalon S; Giraudeau B; Majorel C; Tafani M; Bezard E; Esquerré JP; Baulieu JL
    J Nucl Med; 2003 May; 44(5):663-70. PubMed ID: 12732666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson's disease.
    de Laat B; Hoye J; Stanley G; Hespeler M; Ligi J; Mohan V; Wooten DW; Zhang X; Nguyen TD; Key J; Colonna G; Huang Y; Nabulsi N; Patel A; Matuskey D; Morris ED; Tinaz S
    NPJ Parkinsons Dis; 2024 Feb; 10(1):34. PubMed ID: 38336768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.